In recent clinical trials of ONC201 for diffuse intrinsic pontine glioma (DIPG), patients were shown to invariably develop resistance to ONC201 mediated by PI3K/Akt hyperactivation. Here, AKT1 is linked to diffuse intrinsic pontine glioma.